AstraZeneca: positive data in breast cancer

(CercleFinance.com) - On Wednesday AstraZeneca announced that its investigational tablet camizestrant had shown positive results in a Phase III clinical trial for a difficult-to-treat form of breast cancer.


The biopharmaceutical group reports that camizestrant combined with one of three commercially available CDK4/6 inhibitors (palbociclib, ribociclib or abemaciclib) resulted in a statistically significant and clinically relevant improvement in progression-free survival in treated patients.

The trial involved 315 participants with HR-positive and HER2-negative advanced breast cancer.

For Susan Galbraith, AstraZeneca's Head of Oncology R&D, these are "impressive" results, paving the way for a new first-line treatment for patients whose tumors develop ESR1 mutations during therapy.

AstraZeneca shares gained 0.5% on the London Stock Exchange following the announcement.


Copyright (c) 2025 CercleFinance.com. All rights reserved.